All In Biotech

Drug Trial Radar · NCT03613662

A Research Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102

An Open-label, Single-arm Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects With Lumbosacral Radiculopathy

Last checked: Nov 19, 2026Latest source record: Jan 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

19

Actual

Start

Jul 13, 2018

Primary completion

Mar 15, 2019

Study completion Mar 15, 2019

Sponsor

Lead sponsor
Semnur Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials; Scilex Pharmaceuticals, Inc.
First posted
Aug 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm, repeat dose study to characterize the pharmacodynamics and safety/tolerability of SP-102 administered by epidural injection.

Conditions

  • Lumbosacral Radicular Pain

Interventions

  • SP-102Drug

    Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Plasma Cortisol Concentrations From BaselineTime frame: 12 Weeks
  2. Change in Blood Glucose Levels From BaselineTime frame: 12 Weeks
  3. Change in White Blood Cell (WBC) Levels From BaselineTime frame: 12 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Semnur Research Site 1

    Boise, Idaho

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.